An observational study of ivig in view of efficay in guillain barre syndrome

Abstract

Background⁽¹⁾: Guillain-Barré syndrome is an inflammatory polyradiculoneuropathy characterized by rapidly evolving weakness and areflexia, reaching nadir within 4 weeks. In Guillain-Barré syndrome, the body's immune system attacks part of the peripheral nervous system. This can result in muscle weakness and loss of sensation in both upper and lower limbs. In this condition the immune system produces harmful antibodies that attack the nerves. The most effective treatment for Guillain-Barré syndrome is intravenous immunoglobulin, that is obtained from human plasma that is pooled from 3000-10,000 donors, it is widely used in the treatment of auto-immune neuromuscular diseases. Methods: This is a prospective observational research study to find out the efficacy outcomes of the drug intravenous immunoglobulin in guillain barre syndrome. Results: Among the patients who were treated with IVIG, 88%, had a good outcome i.e., symptoms are decreased and,10% (21) has poor outcome i.e., some of them symptoms are persistant. Among 50 patients most of the patients i.e., 25 (50%) have shown symptomatic relief on Day 5 least patients 5 (10%) patients on Day7. Among 50 patients, 43 patients have a muscle power >= 4 They constitute 86% of the total patients registered, we also noticed that the predominant treatment that are exhibiting therapeutic achievements were IVIg. Conclusion: This study on state of the drug IVIg given in the condition of guillain barre syndrome condition has shown the therapeutic efficacy prominently for 5 consecutive days which is given in parentral route as matter of fact to meet the disease condition and prevent its progression. Most of the patients have shown symptomatic relief on Day 5 of IVIg treatment, majority of the patients have progressed immensely obtaining great results, and the patients have a muscle power >= 4, which shows greater recovery of the patients with IVIg treatment.

Keywords: Guillain-Barré syndrome, IVIg, immunoglobulin